FDA SHOULD INCREASE ROLE IN DISCLOSURE OF NEGATIVE CLINICAL TRIALS, JAMA EDITORIAL URGES; NIFEDIPINE CONTRAINDICATION FOR HYPERTENSIVE EMERGENCY RE-EMPHASIZED
Executive Summary
A Journal of the American Medical Association editorialist is urging FDA to increase its role in disseminating information about clinical trial failures that could identify inappropriate uses of approved drugs.